| First Author | Hardy IR | Year | 2014 |
| Journal | J Immunol | Volume | 192 |
| Issue | 4 | Pages | 1641-50 |
| PubMed ID | 24442438 | Mgi Jnum | J:209362 |
| Mgi Id | MGI:5567021 | Doi | 10.4049/jimmunol.1302672 |
| Citation | Hardy IR, et al. (2014) Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol 192(4):1641-50 |
| abstractText | B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy. |
